Status:
COMPLETED
AZD8529 Single Ascending Dose Study in Healthy Japanese Subjects
Lead Sponsor:
AstraZeneca
Conditions:
Healthy
Eligibility:
MALE
20-45 years
Phase:
PHASE1
Brief Summary
This is a Phase I, double-blind, placebo-controlled, randomised within each dose group, single ascending dose study, with the objective to assess the safety, tolerability and pharmacokinetic profile o...
Eligibility Criteria
Inclusion
- Healthy male Japanese subjects aged 20 to 45 years (inclusive)
- Have a body mass index (BMI) between 18 and 27 kg/m 2 (inclusive) and weigh at least 50 kg.least 50 kg.
Exclusion
- History of any clinically significant disease or disorder which, in the opinion of the Investigator, may either put the subject at risk because of participation in the study, or influence the results or the subject's ability to participate in the study.
- Any clinically relevant abnormalities in physical examinations, vital signs, clinical chemistry, haematology or urinalysis as judged by the Investigator and/or Sponsor.
- Smoking in excess of 5 cigarettes per day or the equivalent within 28 days of Day 1.
Key Trial Info
Start Date :
April 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2009
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT00886756
Start Date
April 1 2009
End Date
July 1 2009
Last Update
August 19 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
London, United Kingdom